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Background. In patients with known or suspected risk factors for gastrointestinal stenosis, the PillCam patency capsule (PC) is
given before a video capsule endoscopy (VCE) in order to minimize the risk of capsule retention (CR). CR is considered unlikely
upon excretion of the PC within 30 hours, excretion in an undamaged state after 30 hours, or radiological projection to the colon.
Methods.We performed a retrospective analysis of 38 patients with risk factors for CR, who received a PC from 02/2013 to 04/2015
at KlinikumAugsburg. Results. Sixteen of our 38 patients observed a natural excretion after a mean time of 34 hours past ingestion.
However, only 8 patients observed excretion within 30 hours, as recommended by the company. In 20 patients passage of the PC
into the colon was shown via RFID-scan or radiological imaging (after 33 and 45 hours, resp.). Only 2 patients showed a pathologic
PC result. In consequence, 32 patients received the VCE; no CR was observed. Conclusion. Our data indicates that a VCE could
safely be performed even if the PC excretion time is longer than 30 hours and the excreted PC was not screened for damage.
1. Introduction
Video capsule endoscopy (VCE) is a well-established diag-
nostic tool in small bowel diagnostics.
The main indications are obscure gastrointestinal bleed-
ing, suspected isolated small bowel Crohn’s disease, compli-
cated celiac disease, and surveillance in polyposis syndromes
[1–4]. It is a noninvasive diagnostic toolwith only rare adverse
events [5]. The most important but still rare complication
is capsule retention (CR). CR is defined as a remaining
of the capsule in the gastrointestinal (GI) tract for longer
than two weeks or the need for surgical removal due to
small bowel obstruction [6]. Until now only few cases of
symptomatic capsule retention have been described [7, 8].
In healthy adults the rate is almost 0%. The main risk
factor for CR is known or suspected Crohn’s disease with
a risk of up to 13% in some studies [2, 9]. In patients with
symptomatic small bowel obstruction the risk increases to
over 16%. Further risk factors include NSAID enteropathy,
extensive previous abdominal surgery, intestinal ischemia,
volvulus, and a history of abdominal radiotherapy [6, 8,
10–12]. However, some of these may not be known before
VCE.
To minimize the risk of retention in patients with risk
factors for CR a PillCam patency capsule (GIVEN Imaging,
Ltd., Yokneam, Israel) has been developed. The PC is a self-
dissolving dummy capsule with the same size as the VCE.
The capsule is made mainly of barium sulphate and lactose
anhydrous. It contains a so called radiofrequency identifi-
cation (RFID), which can be detected via an extracorporeal
RFID scanner. 30 hours after ingestion a built-in timer opens
two small holes in the capsule’s surface. The digestive juice
can enter the capsule and starts to dissolve the capsule, thus,
preventing small bowel obstruction potentially caused by the
PC. So far, only a few cases of continued retaining of the PC
or temporary intestinal occlusion have been reported [13, 14].
According to the company, capsule retention of the VCE
is most unlikely, if the PC has passed the intestinal tract
within 30 hours or if the excreted capsule is still intact without
signs of disintegration [10]. Studies showed that the sensitivity
of the PC in detecting a stenosis is at least comparable to
other diagnostic tools such as barium small bowel follow-
through (SBFT) or CT or MRI small bowel imaging in
patients with known risk factors for CR [10, 15]. A large
multicenter study with 106 patients indicated that even if a
stricture is radiologically diagnosed via CT or SBFT, no CR
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occurred during VCE when the PC was excreted undamaged
after more than 30 hours.
The average total intestinal transit time of the PC in
this study was 40 hours. Forty-three patients excreted the
capsule within 60 hours after ingestion [12]. In this case
the manufacturer demands the PC to be investigated for
damage. However, the total transit time of the GI tract varies
strongly depending on the general health condition, age,
gender, and food consistency. Women seem to have longer
transit time, whereas aging seems to accelerate the gastric and
small intestinal transit [16]. The gastric passage time varies
from almost instantly (fluids) to as much as 6 hours (solid
and fatty foods). Passage of the small intestine usually takes
about 5 hours but can take up to 7 hours in healthy adults [16].
The colon transit time again is highly variable ranging from
12 to 48 hours but can reach up to 80 hours [16].
Taking into account these highly variable physiological
transit times, the cutoff of 30 hours past ingestion, as
indicated by the manufacturer, can easily be exceeded in
healthy subjects. It may be too short for routine clinical use.
In this retrospective study we analyzed our experiences
with the APC in order to establish an algorithm suitable for a
real-world scenario.
2. Methods
2.1. Study Population. All patients who had a known or
suspected risk factor for CR and who received a PC from
02/2013 to 04/2015 at the Klinikum Augsburg were included
in this study. Inclusion criteriawere a knownor suspected risk
factor for a CR and the possibility of swallowing a PC. Risk
factors for CR were previous abdominal operation, known or
suspectedCrohn’s disease, long termor high doseNSAIDuse,
suspected tumor of or in close proximity to the GI tract upon
imaging, and a history of ileus or subileus.
All open abdominal surgeries except appendectomy were
considered as a risk factor for CR. Laparoscopic cholecys-
tectomy or appendectomy as well as open appendectomy
was considered as a risk factor only if combined with other
existing risk factors.
As for long term NSAID use, we counted the daily intake
of ASS 100 for more than half a year. As for high dose NSAID
we considered a daily intake of ASS 500, as well as Ibuprofen
or Diclofenac for over two weeks lately.
Patients with an implantable cardioverter defibrillator
(ICD) or a pacemaker were not excluded from the study
although no RFID-scan could be performed.
Patients who had problems swallowing or who did not
have any risk factors were not included in this study.
All patients gave written informed consent prior to the
intervention. The study was conducted in accordance with
the ethical principles of the Declaration of Helsinki and in
compliance with good clinical practice and local regulations.
Values are expressed as mean ± standard deviation or
mean (range).
2.2. PC Procedure. In our clinic, administration of a PC
before VCE is indicated in case of any risk factors for a CR or
a history of subileus/ileus. Prior to the intervention, patients
were interviewed for possible swallowing problems or risk
factors such as mediastinal radiotherapy or neurological
disorders. Also, they were asked about a pacemaker or an
ICD. All patients gave written informed consent. Before the
intake of a PC, a negative scan was confirmed with the
RFID scanner. Patients were allowed to eat and take their
medication as usual butwere asked to drink plenty.No special
bowel preparations were performed. Patients who did not
excrete the PC within 30 hours were scanned with the RFID
scanner at 30 to 60 hours past ingestion. In case of a still
positive scan, an abdominal X-ray was performed. Patients
carrying a pacemaker or ICD were not scanned but X-rayed
directly if the PC was not excreted within 60 hours. PCs
excreted between 30 and 60 hours past ingestion were not
screened for damage such as a disintegrated body. If the PC
was excreted within 60 hours or radiologically projected to
the colon the planned VCE was initiated.
3. Results
The present study is a retrospective single-center analysis at
KlinikumAugsburg.We included 38 patients from 02/2013 to
04/2015, who received a PC prior to VCE because of a known
or suspected risk factor for CR.Themain indications for VCE
were anemia/gastrointestinal bleeding (26 patients, 68%) and
suspected Crohn’s disease of the small intestine (10 patients,
26%). Our electronic database identified 42 patients who
were scheduled for PC before VCE. Two patients had to be
excluded because they could not swallow the PC. Two other
patients were excluded because they intentionally aborted
the diagnostic work-up and the analysis of the PC could not
be completed. Thus, 38 patients met the entry criteria. The
median age of the included patients was 61.5 years (range 14–
88).
The patients received a PC before a VCE because of at
least one risk factor for CR. Out of the 38 patients included in
this study 21 patients (55%) had previous abdominal surgery,
11 patients (29%) had suspected or known Crohn’s disease, 8
patients (21%) had suspected NSAID enteropathy, 4 patients
(11%) had a suspected tumor in previous imaging, and 2
patients (5%) had had history of subileus/ileus.
Out of the 21 patients with previous abdominal surgery
11 patients had had multiple surgeries. Out of the 10 patients
with a single abdominal surgery two had had a laparoscopic
cholecystectomy, which was not considered a risk factor
by itself. These patients had other risk factors as well. The
remaining 8 of these patients had had additional surgeries
such as small bowel resection or gastrojejunostomy.
Three of the 8 patients with suspected NSAID enteropa-
thy had a long-time daily intake of ASS 100mg alone. The
other 5 of these patients had other accompanying risk factors
for CR.
Out of the four patients with an abdominal tumor
manifestation upon imaging two had a duodenal stenosis due
to amalignant tumor infiltration by an unknownprimary and
pancreatic pseudocyst, respectively. Two other patients had a
large adjacent lymphadenopathy with possible stenosis.
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Table 1: Demographic and clinical characteristics of the study population: the main indications for the planned VCE were suspected Crohn’s
disease of the small intestine or gastrointestinal bleeding. All 38 included patients had at least one risk factor for a capsule retention.
Parameter
Age [years] 61,5 [14–88]
Sex [male/female] 17/21
Indication for VCE
Suspected CD of the small bowel 10 (26%)
Anemia/gastrointestinal bleeding 26 (68%)
Suspected tumor 2 (5%)
Documented risk factor for capsule retention
One documented risk factor for capsule retention 8 (21%)
More than one documented risk factor for capsule retention 30 (79%)
Suspected or known Crohn’s disease 11 (29%)
Previous abdominal surgery 21 (55%)
Multiple previous abdominal surgeries 11 (29%)
Previous subileus or ileus 2 (5%)
Suspected tumor in imaging 4 (11%)
High dose and/or longtime NSAID use 8 (21%)
VCE: video capsule endoscopy, CD: Crohn’s disease, and NSAID: nonsteroidal anti-inflammatory drug.
In conclusion, all 38 patients had documented risk factors
for capsule retention. Eight patients hadmultiple risk factors.
The patients’ characteristics are summarized in Table 1.
Prior to the capsule intake, all RFID-scans were negative.
Three patients were not scanned due to an implanted ICD or
pacemaker.
Fourteen patients excreted the PC before the second
RFID-scan at 30–60 hours past ingestion. The mean time of
excretionwas 33 hours (range 8–57).While 2 of the remaining
patients with no excretion could not be scanned due to
an implanted pacemaker or ICD, 22 patients underwent a
second scan. In 6 patients the scan was negative, indicating
that the PC had been excreted despite no actual observation
in the stool. One patient had a positive scan but observed
excretion shortly after. The remaining 17 patients underwent
an abdominal X-ray at an average time of 45 hours past
ingestion. In 13 out of these 17 patients the X-ray did not
show the capsule or projected it to the colon, thus, indicating
complete small bowel passage. One X-ray did not clearly
differentiate between colon and small bowel location. This
patient underwent a CT scan, which localized the capsule
to the colon. Three patients’ X-rays projected the PC to
the small intestine. One patient observed capsule excretion
shortly thereafter, at 40 hours past ingestion. The other two
patients did not observe an excretion over the course of their
stay. This was considered as capsule retention (CR).
One of these two patients with a pathologic PC examina-
tionwas a 79-year-oldwomanwith suspectedCrohn’s disease.
Repeated RFID-scans and X-rays did indicate capsule reten-
tion until the 13th day after ingestion of the PC. However, the
patient developed no clinical symptoms such as abdominal
pain or nausea and eventual complete disintegration could
be assumed.The other patient was amultimorbid 57-year-old
woman who had initially been admitted to the hospital due
to a urinary tract infection. She had a history of endometrial
carcinoma with hysterectomy and a colorectal carcinoma
with an extirpation of the rectum. A VCE was indicated
due to occult gastrointestinal bleeding without sufficient
explanation in upper or lower colonoscopy. A CT scan
revealed a relapse of the endometrial carcinoma with pul-
monicmetastasis.This patient rejected any further diagnostic
or therapeutic interventions andopted to be transferred to the
palliative care unit.
The study results are summarized in Figure 1.
In summary, 38 patients received a PC. Natural excretion
was observed in 14 patients (37%) before the second RFID-
scan with an average excretion time of the GI tract being 33
hours. In total 16 patients (42%) observed a natural excretion
within an average passage time of 34 hours (range 8–57 hours)
(Table 2). Eight patients had a total transit time of less than
30 hours.The second RFID-scan was performed after a mean
time of 33 hours past ingestion.The scanwas positive in 16 out
of 22 patients (73%). Seventeen (45%) of the total 38 patients
underwent an abdominal X-ray after a mean time of 45 hours
past ingestion. This was negative in 13 patients (76%). One
X-ray gave an uncertain result so a CT scan was performed.
In 3 patients (11%) the X-ray projected the capsule to the
small bowel, thus indicating capsule retention. One of these 3
patients observed a natural excretion after the examination.
Thirty-two (84%) of the 38 patients with PC finally
underwent a VCE.
Besides the two pathologic PC examinations two other
patients were afraid of capsule retention because of a longer
PC passage than 30 hours. One patient developed a severe
sepsis and died over the course of his stay. Another patient
developed a subileus.
In total 6 patients were excluded fromVCE. In the 32VCE
after PCno complication or signs forVCE retention occurred.
The mean small bowel passage time of the VCE was found to
be 4.4 hours. The findings of the VCE are shown in Table 2.
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Figure 1: Confirmation of patency of the small intestine by using the patency capsule (PC): 38 patients (pts) with an indication for VCE and
risk factors for capsule retention (CR) received a PC. In 36 patients complete bowel passage could be confirmed using the PC. Sixteen
patients observed natural excretion, 14 of whom before any diagnostic steps concerning possible retention. Only 2 patients showed a
pathologic PC: one with suspected Crohn’s disease, who gave positive RFID-scans until 13th day past ingestion, and one with a relapse
of an endometrium carcinoma. PC: patency capsule, pts: patients, h: hours, VCE: video capsule endoscopy, CR: capsule retention, RFID:
radiofrequency identification, and ø: mean time.
4. Discussion
The feared but rare complication of capsule endoscopy is
capsule retention (CR) in the small bowel with consecutive
obstruction. CR is defined as a remaining of the capsule inside
the GI tract for over two weeks or the need for further steps
such as surgical removal [6, 8].Therefore the PillCampatency
capsule (PC)was developed in order to test for impeded small
bowel passage in patients with risk factors for CR prior to
VCE. Several studies have shown that a PC can minimize
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Table 2: PC and VCE findings: transit time of the PC shown by
observed natural excretion, negative RFID-scan, or projection of
the PC to the colon via radiological examination. Furthermore the
findings of the VCE are shown. No complications appeared during
the VCE.
Totally performed PC 38
Natural excretion
No observed excretion 22 (58%)
Observed excretion 16 (42%)
PC with transit time <30 hours 8
Mean time to observed excretion 34 hours
RFID-scan
Total 22
Not possible (ICD, pacemaker) 2
Negative 6 (27%)
Positive 16 (73%)




Uncertain, so a CT was performed afterwards 1 (6%)
Positive 3 (18%)
Mean time performed after 45 hours
Transit time of the 38 performed PCs
PC with transit time <30 hours 8 (21%)
PC with transit time >30 hours and <72 hours 28 (74%)
PC with transit time >72 hours or retention 2 (5%)
VCE
No VCE after PC 6 (16%)
VCE after PC 32 (84%)
VCE findings
No pathologic finding 10 (31%)
Angiodysplasia 8 (25%)
Active bleeding 2 (6%)
Crohn’s disease typical findings 7 (22%)
NSAID enteropathy typical findings 2 (6%)
Unspecific inflammation/ulcers 2 (6%)
Malignoma of the duodenum 1 (3%)
Complications 0 (0%)
Mean small bowel passage time 4.4 hours
PC: patency capsule, RFID: radiofrequency identification, VCE: video
capsule endoscopy, CR: capsule retention, and NSAID: nonsteroidal anti-
inflammatory drug.
the risk of CR to a high extent [8, 12, 17]. Another benefit of
the PC is the lack of radiation exposure for the patient. The
negative predictive value of a PC is comparable if not better
compared to other diagnostic tools like small bowel follow-
through (SBFT) in several retrospective studies [10, 15, 18].
Only a few cases of complications caused by the PC, such as
temporary intestinal obstruction, have been reported [13, 14].
A study by Herrerias et al. in 2008 of 106 patients with
known intestinal strictures could show that a VCE could
be given if the PC is excreted undamaged after 30 hours
[12]. Our data now show that in clinical routine only 42%
of patients observe a natural excretion. Furthermore only
8 patients observed an excretion within the 30 hours past
ingestion which is recommended by the company. In the
other 8 patients who observed excretion after more than 30
hours, the capsule should have been examined for damage,
according to the company’s manual. Furthermore, 58% of
patients did not detect the excreted capsule in their stool, so
no inspection of the capsule would have been possible. Other
studies reported a PC detection rate in the excrements of
around 50% [19, 20]. In order to increase the detection rate the
stool should be examined more closely; however, acceptance
of such a procedure as well as the practicability in a regular
clinical setting is very low.
In our study, patients were given a VCE if the PC was
excreted in less than 60 hours or if the PC was radiologically
projected to the colon. So 32 of the 38 patients with a PC
underwent a VCE. Two patients showed a pathologic PCwith
no excretion within 72 hours. Two other patients rejected
the VCE because their PC passage time was longer than 30
hours. One patient showed clinical signs of an ileus before
administration of the VCE. Another patient died of severe
sepsis probably because of a clostridium-colitis before a VCE
was given. In the following 32 VCE no patient showed any
signs for capsule retention. The finding that a VCE can be
given, even if the PC is excreted in more than 40 hours, is
consistent with findings in the literature [12, 17].
Use of bowel preparation like polyethylene glycol-based
purge has been shown to improve the diagnostic gain of
VCE but does not accelerate the gastric as well as small
bowel capsule transit time [21, 22]. It would be interesting
to know whether purging could lead to an increased capsule
detection rate in the stool within the suggested 30 hours past
ingestion. The official recommendation suggests a liquid diet
for 20 hours and a 2-hour period of nil by mouth before and
after the ingestion of the PC. Our patients were allowed to
drink and eat on a regular manner. No special medication
or purgative preparations were performed in accordance with
other studies [20].
Limitations of this study are that it is a retrospective elec-
tronic data-based, single-center study with only 38 patients.
However, a prospective randomized study would not be
feasible due to ethical complications. Furthermore there is an
inconsistency of time points of further diagnostic steps after
the ingestion of the PC due to the clinical setting.
5. Conclusion
In summary, patients with known risk factors for gastroin-
testinal stenosis were given the PillCam patency capsule
before the video capsule endoscopy in order to minimize the
risk of capsule retention. Referring to the official recommen-
dations of the company capsule retention of the video capsule
endoscopy is most unlikely if the patency capsule is excreted
within 30 hours, radiologically projected to the colon, or
excreted in an undamaged state after 30 hours. According
to our results we suggest that performing a video capsule
endoscopy is safe even if the patency capsule is excreted after
more than 30 hours and is not screened for damage when
following our protocol. However, more data is needed.
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